Stratos Wealth Advisors LLC Decreases Stake in Bristol Myers Squibb Company $BMY

Stratos Wealth Advisors LLC cut its position in Bristol Myers Squibb Company (NYSE:BMY) by 1.6% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 21,289 shares of the biopharmaceutical company’s stock after selling 355 shares during the period. Stratos Wealth Advisors LLC’s holdings in Bristol Myers Squibb were worth $985,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Brighton Jones LLC raised its stake in Bristol Myers Squibb by 33.4% in the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after buying an additional 4,935 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Bristol Myers Squibb by 18.8% in the 1st quarter. GAMMA Investing LLC now owns 39,685 shares of the biopharmaceutical company’s stock valued at $2,420,000 after acquiring an additional 6,267 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its position in shares of Bristol Myers Squibb by 17.0% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 550,613 shares of the biopharmaceutical company’s stock worth $33,582,000 after acquiring an additional 80,087 shares in the last quarter. Avior Wealth Management LLC raised its position in shares of Bristol Myers Squibb by 38.9% during the 1st quarter. Avior Wealth Management LLC now owns 5,503 shares of the biopharmaceutical company’s stock worth $336,000 after acquiring an additional 1,542 shares in the last quarter. Finally, Advisor Resource Council purchased a new stake in Bristol Myers Squibb during the first quarter worth approximately $245,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

BMY has been the topic of a number of research analyst reports. Dbs Bank raised shares of Bristol Myers Squibb to a “moderate buy” rating in a report on Thursday, October 2nd. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Bristol Myers Squibb in a research report on Tuesday, October 14th. Daiwa Capital Markets cut shares of Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price target for the company. in a research report on Tuesday, August 5th. Daiwa America lowered Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 5th. Finally, Morgan Stanley reissued a “hold” rating on shares of Bristol Myers Squibb in a report on Thursday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and fourteen have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $57.23.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of the company’s stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the completion of the transaction, the executive vice president owned 167,379 shares in the company, valued at approximately $7,922,048.07. This represents a 25.07% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.09% of the company’s stock.

Bristol Myers Squibb Price Performance

Shares of NYSE:BMY opened at $43.63 on Friday. Bristol Myers Squibb Company has a one year low of $42.96 and a one year high of $63.33. The stock has a market capitalization of $88.80 billion, a price-to-earnings ratio of 17.59, a PEG ratio of 2.26 and a beta of 0.33. The company has a 50-day simple moving average of $46.07 and a 200-day simple moving average of $47.47. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.07 by $0.39. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The firm had revenue of $12.27 billion for the quarter, compared to analysts’ expectations of $11.32 billion. During the same quarter in the previous year, the firm posted $2.07 EPS. The firm’s revenue for the quarter was up .6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. On average, analysts predict that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 3rd. Investors of record on Friday, October 3rd will be given a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a yield of 5.7%. The ex-dividend date is Friday, October 3rd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 100.00%.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.